JP2023522212A5 - - Google Patents

Info

Publication number
JP2023522212A5
JP2023522212A5 JP2022563016A JP2022563016A JP2023522212A5 JP 2023522212 A5 JP2023522212 A5 JP 2023522212A5 JP 2022563016 A JP2022563016 A JP 2022563016A JP 2022563016 A JP2022563016 A JP 2022563016A JP 2023522212 A5 JP2023522212 A5 JP 2023522212A5
Authority
JP
Japan
Prior art keywords
seq
cdr
chain variable
variable region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022563016A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522212A (ja
JP7772715B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/027801 external-priority patent/WO2021212053A2/en
Publication of JP2023522212A publication Critical patent/JP2023522212A/ja
Publication of JP2023522212A5 publication Critical patent/JP2023522212A5/ja
Priority to JP2025187491A priority Critical patent/JP2026056615A/ja
Application granted granted Critical
Publication of JP7772715B2 publication Critical patent/JP7772715B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022563016A 2020-04-17 2021-04-16 治療用musk抗体 Active JP7772715B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025187491A JP2026056615A (ja) 2020-04-17 2025-11-06 治療用musk抗体

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063011986P 2020-04-17 2020-04-17
US63/011,986 2020-04-17
US202063038633P 2020-06-12 2020-06-12
US63/038,633 2020-06-12
US202063112375P 2020-11-11 2020-11-11
US63/112,375 2020-11-11
PCT/US2021/027801 WO2021212053A2 (en) 2020-04-17 2021-04-16 Therapeutic musk antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025187491A Division JP2026056615A (ja) 2020-04-17 2025-11-06 治療用musk抗体

Publications (3)

Publication Number Publication Date
JP2023522212A JP2023522212A (ja) 2023-05-29
JP2023522212A5 true JP2023522212A5 (cg-RX-API-DMAC7.html) 2024-06-21
JP7772715B2 JP7772715B2 (ja) 2025-11-18

Family

ID=75850676

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022563016A Active JP7772715B2 (ja) 2020-04-17 2021-04-16 治療用musk抗体
JP2025187491A Pending JP2026056615A (ja) 2020-04-17 2025-11-06 治療用musk抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025187491A Pending JP2026056615A (ja) 2020-04-17 2025-11-06 治療用musk抗体

Country Status (12)

Country Link
US (2) US11492401B2 (cg-RX-API-DMAC7.html)
EP (1) EP4136115A2 (cg-RX-API-DMAC7.html)
JP (2) JP7772715B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230028217A (cg-RX-API-DMAC7.html)
CN (1) CN115843268A (cg-RX-API-DMAC7.html)
AU (1) AU2021256049A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021065A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175597A1 (cg-RX-API-DMAC7.html)
IL (1) IL297295A (cg-RX-API-DMAC7.html)
MX (1) MX2022011856A (cg-RX-API-DMAC7.html)
PH (1) PH12022552483A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021212053A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12022552483A1 (en) * 2020-04-17 2024-02-05 argenx BV Therapeutic musk antibodies
US20240279331A1 (en) * 2021-06-11 2024-08-22 The Regents Of The University Of California Antibodies that stimulate nk cell-mediated cytotoxicity
MX2024008933A (es) * 2022-01-28 2024-09-30 argenx BV Anticuerpos anti-musk para uso en el tratamiento de trastornos neuromusculares.
WO2023218099A1 (en) * 2022-05-13 2023-11-16 argenx BV In utero treatment of a fetus having genetic disease/neuromuscular disease
WO2024235870A1 (en) * 2023-05-15 2024-11-21 Argenx B.V. Antibodies for use in agrin-deficient disorders
WO2025129132A1 (en) * 2023-12-14 2025-06-19 Invenra Inc. Multispecific binding agents that target ctla4 and/or cd25 and uses thereof
WO2026152042A1 (en) 2025-01-10 2026-07-16 Scholar Rock, Inc. A novel class of musk agonists and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
US6737249B1 (en) 1997-08-22 2004-05-18 Genentech, Inc. Agonist antibodies
US6624819B1 (en) 2000-05-01 2003-09-23 Broadcom Corporation Method and system for providing a flexible and efficient processor for use in a graphics processing system
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1411851B1 (en) 2001-08-03 2006-11-02 Tyco Healthcare Group LP Marker for use with a tissue marking apparatus
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
NZ602220A (en) 2010-03-11 2014-10-31 Rinat Neuroscience Corp Antibodies with ph dependent antigen binding
JP2011207769A (ja) 2010-03-29 2011-10-20 Arubion:Kk 化粧料及び皮膚外用剤
WO2013074636A1 (en) 2011-11-14 2013-05-23 New York University Muscle specific receptor kinase and modulation thereof
WO2015039015A2 (en) 2013-09-13 2015-03-19 New York University Methods for treating muscle specific receptor kinase myasthenia gravis
PH12022552483A1 (en) * 2020-04-17 2024-02-05 argenx BV Therapeutic musk antibodies

Similar Documents

Publication Publication Date Title
AU2022241522B2 (en) Bispecific antibody to a-syn/igf1r and use thereof
US20200347130A1 (en) CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof
JP2022512132A5 (cg-RX-API-DMAC7.html)
JP2024520188A5 (cg-RX-API-DMAC7.html)
JP2020513791A5 (cg-RX-API-DMAC7.html)
KR20160127825A (ko) 항-mcam 항체 및 관련된 사용 방법
RS57026B1 (sr) Anti-n3pgiu amiloid beta peptid antitela i njihova upotreba
JP2024001073A5 (cg-RX-API-DMAC7.html)
AU2018351417B2 (en) Anti-MSLN antibody and pharmaceutical composition for cancer treatment comprising same
JP2024515536A5 (cg-RX-API-DMAC7.html)
JP2021511387A5 (cg-RX-API-DMAC7.html)
JP2023519962A5 (cg-RX-API-DMAC7.html)
US10836833B2 (en) Cell engaging binding molecules
JP2023506465A5 (cg-RX-API-DMAC7.html)
JP2024543822A5 (cg-RX-API-DMAC7.html)
JP2022521305A (ja) 抗pd-l1抗体及びその使用
IL312060A (en) Bispecific CD16A binders
JP2023509215A5 (cg-RX-API-DMAC7.html)
JP2025505650A5 (cg-RX-API-DMAC7.html)
JP2025130076A5 (cg-RX-API-DMAC7.html)
CN113966346A (zh) 抗a-syn/igf1r的双特异性抗体及其用途
CN114829405A (zh) 抗bcma/抗4-1bb双特异性抗体及其用途
JP2024543828A5 (cg-RX-API-DMAC7.html)
JP2024543134A5 (cg-RX-API-DMAC7.html)
KR20210031913A (ko) 항-인간 pd-l1 항체 및 그것의 용도